Edwards Lifesciences Stock News

Wells Fargo & Company upgraded shares of Edwards Lifesciences (NYSE:EW) from an equal weight rating to an overweight rating in a research note published on Monday, PriceTargets.com reports. They currently have $126.00 target price on the medical research companys stock. A number of other brokerages have also recently issued reports on EW. Citigroup lifted their []

Edwards Lifesciences (NYSE:EW) was upgraded by analysts at Wells Fargo & Company from an equal weight rating to an overweight rating in a report issued on Monday, The Fly reports. EW has been the topic of several other reports. Citigroup increased their price target on shares of Edwards Lifesciences from $113.00 to $120.00 and gave []

Dublin, Dec. 06, 2021 (GLOBE NEWSWIRE) -- The "United States Cardiovascular Devices Market Forecast 2021-2027, Industry Trends, Growth, Impact of COVID-19, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com''s offering.

RMB Capital Management LLC reduced its holdings in Edwards Lifesciences Co. (NYSE:EW) by 1.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 524,507 shares of the medical research companys stock after selling 6,184 shares during the quarter. Edwards Lifesciences accounts []

Robeco Institutional Asset Management B.V. grew its position in Edwards Lifesciences Co. (NYSE:EW) by 18.1% during the 3rd quarter, HoldingsChannel reports. The firm owned 709,461 shares of the medical research companys stock after purchasing an additional 108,902 shares during the quarter. Robeco Institutional Asset Management B.V.s holdings in Edwards Lifesciences were worth $80,317,000 at the []

Raymond James Trust N.A. boosted its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 1.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 35,621 shares of the medical research companys stock after purchasing an additional 339 shares []

Exchange Traded Concepts LLC increased its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 4.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 34,113 shares of the medical research companys stock after acquiring an additional 1,369 shares during []

Wendell David Associates Inc. raised its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 1.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 70,325 shares of the medical research companys stock after buying an additional 1,200 shares during the period. []

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we look at two

Foundry Partners LLC lessened its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 11.9% in the third quarter, according to its most recent filing with the SEC. The fund owned 9,656 shares of the medical research companys stock after selling 1,303 shares during the period. Foundry Partners LLCs holdings in Edwards Lifesciences were worth []

Transcatheter Aortic Valve Replacement Market is projected to boom at a CAGR +12% by the timeline of 2021-28. Transcatheter aortic valve replacement (TAVR) is a minimally invasive procedure to replace a narrowed aortic valve that fails to open properly (aortic valve

Thrivent Financial for Lutherans reduced its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 5.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,815,102 shares of the medical research companys stock after selling 105,545 shares during the quarter. Thrivent Financial []

Field & Main Bank raised its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 26.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 475 shares of the medical research companys stock after acquiring an additional 100 shares during the quarter. Field & []

Gofen & Glossberg LLC IL lessened its stake in Edwards Lifesciences Co. (NYSE:EW) by 23.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 5,431 shares of the medical research companys stock after selling 1,700 shares during the quarter. Gofen & Glossberg LLC ILs holdings []

Edwards Lifesciences Co. (NYSE:EW) Director Nicholas J. Valeriani bought 1,500 shares of the companys stock in a transaction that occurred on Wednesday, November 24th. The stock was bought at an average cost of $112.23 per share, for a total transaction of $168,345.00. The purchase was disclosed in a document filed with the Securities & Exchange []